Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Borofalan (10B) - Stella Pharma

Next Previous
Drug Profile

Borofalan (10B) - Stella Pharma

Alternative Names: Borofalan - Stella Pharma; SPM-011; Steboronine

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stella Pharma
  • Developer Osaka University; Stella Pharma; Sumitomo Heavy Industries
  • Class Amines; Antineoplastics; Borates; Propionic acids; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Glioma; Haemangiosarcoma
  • No development reported Malignant melanoma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Malignant-melanoma(In the elderly, In adults) in Japan (IV)
  • 18 Nov 2024 Stella Pharma and TAE Life Sciences plans a clinical trial in European union and USA in 2026
  • 14 Nov 2024 Stellas Pharma and Tae life science enters into development and collaboration agreement for Borofalan (10B) in USA and European union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top